Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H2B2
UPID:
SYT4_HUMAN
Alternative names:
Synaptotagmin IV
Alternative UPACC:
Q9H2B2; B4DEU3; Q9P2K4
Background:
Synaptotagmin-4, an alternative name Synaptotagmin IV, plays a crucial role in neuronal dense core vesicles (DCVs) mobility. It interacts with KIF1A and is regulated by phosphorylation through MAPK8/JNK1, which modulates its interaction with KIF1A and DCVs capture to synapses. Additionally, it contributes to dendrite formation by melanocytes.
Therapeutic significance:
Understanding the role of Synaptotagmin-4 could open doors to potential therapeutic strategies.